Patents Examined by Satyanarayana R. Gudibande
  • Peptidomimetic macrocycles with improved properties
    Patent number: 9458202
    Abstract: The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: October 4, 2016
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Huw M. Nash, David Allen Annis, Rosana Kapeller-Libermann, Tomi K. Sawyer, Noriyuki Kawahata
  • Cyclosporin derivatives
    Patent number: 9453051
    Abstract: The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: September 27, 2016
    Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Lead Discovery Center GmbH
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel
  • Injectable aqueous ophthalmic composition and method of use therefor
    Patent number: 9446093
    Abstract: The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 20, 2016
    Assignee: Alcon Research, Ltd.
    Inventors: Masood A. Chowhan, Thomas C. Hohman, Ernesto J. Castillo, Wesley Wehsin Han
  • Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
    Patent number: 9433685
    Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: September 6, 2016
    Assignee: NONO INC.
    Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
  • Tripeptide epoxy ketone protease inhibitors
    Patent number: 9434761
    Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 6, 2016
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
  • Modified toll-like receptor 2 (TLR2) ligands as inhibitors of neutrophil recruitment
    Patent number: 9422335
    Abstract: The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammatory function, while the GM1-binding peptide facilitates endocytosis.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: August 23, 2016
    Assignee: UTI Limited Partnership
    Inventors: Elizabeth M. Long, Stephen M. Robbins, Paul Kubes, Ela Kolaczkowska
  • Compositions and methods for inhibiting proteases
    Patent number: 9409944
    Abstract: In particular, in alternative embodiments, the invention provides pharmaceutical compounds and formulations comprising a family of epoxyketone compounds, which include racemic mixtures or racemates, isomers, stereoisomers, diastereoisomers, derivatives and analogs, and methods for making and using them. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to treat, prevent, reverse and/or ameliorate an infection, disease or condition that can be ameliorated, treated, prevented or reversed by partially or completely inhibiting a chymotrypsin-like protease or a proteasome activity, including e.g.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: August 9, 2016
    Assignee: The Regents of the University of California
    Inventors: William H. Gerwick, Alban R. Pereira-Badilla, Tara Byrum, Frederick A. Valeriote, Michael Kenneth Gilson, Andrew T. Fenley, Bradley S. Moore, Andrew Kale, Hosana Debonsi
  • Polysaccharide-and polypeptide-based block copolymers, vesicles constituted by these copolymers and use thereof
    Patent number: 9403916
    Abstract: The invention relates to a new type of polysaccharide-block-polypeptide diblock copolymer which is bioresorbable or biodegradable and biocompatible, to a method for preparing same, to the micellar vesicles constituted of this copolymer, and to the use thereof for encapsulation, transport, vectorization, and targeting of molecules of interest.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: August 2, 2016
    Assignees: UNIVERSITE DE BORDEAUX, INSTITUT POLYTECHNIQUE DE BORDEAUX
    Inventors: Sébastien Lecommandoux, Jean-François Le Meins, Christophe Schatz, Kamal Kumar Upadhyay
  • Cyclosporine A steroid conjugates
    Patent number: 9402913
    Abstract: The present invention describes Cyclosporine A/steroid hybrid analogs. These single drug entities are formed by connecting a steroid with Cyclosporine A. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: August 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Ken Chow, Liming Wang, Michael E. Garst, Mayssa Attar, Brandon D. Swift
  • Antibiotic conjugates directly linked with steroid drugs
    Patent number: 9402912
    Abstract: The present invention describes novel single drug entities, formed by direct linkage of an antibiotic to a steroidal drug. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. The antibiotic is coupled directly to the steroid drug.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: August 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Ken Chow, Liming Wang, Michael E. Garst, Mayssa Attar, Brandon D. Swift
  • Competitive inhibitor of GP120
    Patent number: 9399663
    Abstract: Peptides and peptide analogs that competitively inhibit HIV protein gp120 and methods for making and using the same.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: July 26, 2016
    Assignee: Georgetown University
    Inventors: Italo Mocchetti, Valeriya Avdoshina
  • Compositions for delivering peptide YY and PYY agonists
    Patent number: 9399054
    Abstract: The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake.
    Type: Grant
    Filed: July 12, 2005
    Date of Patent: July 26, 2016
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Steven Dinh, Huaizhen Wang, Maria Isabel Gomez-Orellana
  • Modulation of synaptic maintenance
    Patent number: 9388238
    Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: July 12, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ben A. Barres, Beth A. Stevens
  • Modulation of synaptic maintenance
    Patent number: 9382313
    Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: July 5, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ben A. Barres, Beth A. Stevens
  • Modulation of synaptic maintenance
    Patent number: 9382314
    Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: July 5, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ben A. Barres, Beth A. Stevens
  • High capacity diketopiperazine microparticles and methods
    Patent number: 9364436
    Abstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: June 14, 2016
    Assignee: MannKind Corporation
    Inventors: Marshall Grant, Paul Menkin, Grayson W. Stowell
  • Pharmaceutical composition containing goserelin for in-situ implant
    Patent number: 9364518
    Abstract: The present invention provides a pharmaceutical composition capable of forming in-situ implant comprising goserelin or its pharmaceutically acceptable salts thereof, biodegradable polymer and a biocompatible organic solvent wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid. The present invention further provides a process for the preparation of pharmaceutical composition capable of forming in-situ implant. A kit containing composition for in-situ implant is provided comprising a first vial comprising a composition comprising a biodegradable polymer and a biocompatible organic solvent; wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid; and a second vial comprising goserelin acetate.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: June 14, 2016
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Sunil S. Nadkarni, Jaya Abraham, Amit Kesarwani, Astha Parmar
  • Compositions for labeling nerves and methods of use
    Patent number: 9353154
    Abstract: The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or nerves and for compositions thereof.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: May 31, 2016
    Assignee: AVELAS BIOSCIENCES, INC.
    Inventors: Jesus Gonzalez, Junjie Liu
  • Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
    Patent number: 9352012
    Abstract: The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: May 31, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Martin Montes, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
  • Method for producing peptide
    Patent number: 9353147
    Abstract: The present invention provides a production method of peptide, which includes the following step (1). (1) removing N-terminal Fmoc group of N-Fmoc C-protected amino acid or N-Fmoc C-protected peptide wherein a C-terminal carboxy group is protected by an anchor group derived from an anchor soluble in halogenated solvents or ether solvents, insoluble in polar solvents and having a molecular weight of not less than 300, with a non-nucleophilic organic base in a halogenated solvent or ether solvent to give a C-protected amino acid or C-protected peptide, neutralizing with an acid, adding N-Fmoc amino acid or N-Fmoc peptide, a condensing agent and a condensation accelerator to the reaction solution after neutralization, and condensing the N-terminal of the C-protected amino acid or C-protected peptide with N-Fmoc amino acid or N-Fmoc peptide to give an N-Fmoc C-protected peptide.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: May 31, 2016
    Assignee: AJINOMOTO CO., INC.
    Inventor: Daisuke Takahashi